Karyopharm Therapeutics Inc.

Biogen Ma Inc.

Galectin Sciences, LLC

Sharon Shechter

Sharon Shacham

Dilara McCauley

Vincent Premaratna Sandanayaka

Erkan Baloglu

William Senapedis

Ori Kalid

Yosef Landesman

Gali Golan

Trinayan Kashyap

Joseph M Johnson

Eliezer Zomer

Peter G Traber

Ryan George

Michael Kauffman

Raphael Nir

Jean-Richard Saint-Martin

Dilârâ McCauley

Dilara Mccauley

Vincent P Sandanyaka

Aspects of the invention relate to compounds, pharmaceutical compositions, methods for the manufacturing of compounds and methods for treatment of various disorders mediated at least in part by one or more galectins.

Compounds for the prevention and treatment of medical disorders and uses thereof

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I.

Hydrazide containing nuclear transport modulators and uses thereof

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Nuclear transport modulators and uses thereof

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.

Compounds for the prevention and treatment of diseases and the use thereof

Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of making and using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.

Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.

Compounds of formula I: and pharmaceutically acceptable salts, hydrates, or solvates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using such compounds and compositions to treat various disorders associated with CRM1 activity.

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Growing community of inventors

Andover, MA, United States of America

Sharon Shechter